This MRI study was performed to evaluate in vivo alterations of the spinal cord in defined subgroups of motor neuron diseases. Standard MRI examinations of the cervical and thoracic spinal cord in sporadic amyotrophic lateral sclerosis (ALS; n = 39), sporadic lower motor neuron disease (LMND; n = 19), Kennedy’s disease (KD; n = 19) and a control group (n = 96) were analyzed with respect to spinal cord signal changes and the thickness of the spinal cord. No significant changes in thickness or signal alterations were observed when comparing ALS, LMND and control groups with one another. However, in KD patients significant upper spinal cord atrophy was detected at the cervical level as compared with all other groups. At the thoracic level, KD patients had significant upper cord atrophy as compared with controls and LMND. Marked atrophy of the upper spinal cord seems to be a feature of the KD-associated central-peripheral distal axonopathy.

Keywords:
Amyotrophic lateral sclerosis, Kennedy’s disease, Lower motor neuron disease, MRI, Spinal cord
1.
Van den Berg-Vos RM, Visser J, Franssen H, de Visser M, de Jong JM, Kalmijn S, Wokke JH, van den Berg LH: Sporadic lower motor neuron disease with adult onset: Classification of subtypes. Brain 2003;126:1036–1047.
2.
Hanemann CO, Ludolph AC: Hereditary motor neuropathies and motor neuron diseases: Which is which. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3:186–189.
3.
Ince PG, Lowe J, Shaw PJ: Amyotrophic lateral sclerosis: Current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998;24:104–117.
4.
Ince PG, Evans J, Knopp M, et al: Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 2003;60:1252–1258.
5.
Terao S, Sobue G, Yasuda T, Kachi T, Takahashi M, Mitsuma T: Magnetic resonance imaging of the corticospinal tracts in amyotrophic lateral sclerosis. J Neurol Sci 1995;133:66–72.
6.
Comi G, Rovaris M, Leocani L: Neuroimaging in amyotrophic lateral sclerosis. Eur J Neurol 1999;6:629–637.
7.
Biondi A, Dormont D, Weitzner I Jr, Bouche P, Chaine P, Bories J: MR Imaging of the cervical cord in juvenile amyotrophy of distal upper extremity. Am J Neuroradiol 1989;10:263–268.
8.
Sperfeld AD, Karitzky J, Brummer D, et al: X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol 2002;59:1921–1926.
9.
Li M, Sobue G, Doyu M, Mukai E, Hashizume Y, Mitsuma T: Primary sensory neurons in X-linked recessive bulbospinal neuropathy: Histopathology and androgen receptor gene expression. Muscle Nerve 1995;18:301–308.
10.
Rowland LP, Shneider NA: Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688–1700.
11.
Schiffer D, Fiano V: Astrogliosis in ALS: Possible interpretations according to pathogenetic hypotheses. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:22–25.
12.
Cosi V, Poloni M, Mazzini L, Callieco R: Somatosensory evoked potentials in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1984;47:857–861.
13.
Buecking A, Pfister R: Sensory ataxia as the initial clinical symptom in X-linked recessive bulbospinal neuronopathy. J Neurol Neurosurg Psychiatry 2000;69:277.
14.
Anannontsak A, Massakulpan P, Aksaranugraha S, Phanthumchinda K: Somatosensory evoked potentials in X-linked recessive bulbospinal neuronopathy: A case demonstration. Electromyogr Clin Neurophysiol 1999;39:393–396.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.